MEDI0639 / AstraZeneca - LARVOL DELTA

Evaluation of anti-cancer stem cell activity of the anti-DLL4 antibody MEDI0639 in a phase I clinical trial of SCLC (ASCO 2016) - Publication-only; P1, N=9; NCT01577745; Sponsor: MedImmune LLC; "Three of the 8 patients also demonstrated > 50% reductions tumor CSC count after MEDI0639 treatment. Expression levels of CSC genes (CD133, EZH2, and ASCL1) were decreased after MEDI0639 treatment in 3 of 7 patients with adequate tumor RNA samples."

P1 data • Oncology

AstraZeneca: H1 FY 2016 Results (AstraZeneca) - Discontinuation in solid tumors due to safety/efficacy reason

Discontinued • Oncology

AstraZeneca: Q4 & FY 2015 Results (AstraZeneca) - Anticipated top-line data from P1 trial (NCT01577745) in adults with advanced solid tumors including SCLC in H2 2016 

Anticipated P1 data • Oncology • Small Cell Lung Cancer